Medicare Launches GLP-1 Weight Loss Drug Program for Seniors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: seekingalpha
- Expanded Drug Coverage: The Centers for Medicare & Medicaid Services announced that starting July 1, millions of seniors will be eligible to receive GLP-1 weight-loss drugs like Wegovy and Zepbound for just $50 per month, significantly enhancing access to weight-loss medications for older Americans.
- Significant Market Impact: The program is expected to add over $1 billion in annual revenue for each of Eli Lilly and Novo Nordisk, further solidifying their dominance in the GLP-1 market, which is projected to generate $150 billion in global sales by 2030.
- Funding Sources: Unlike traditional Medicare, this program is funded by taxpayer dollars and beneficiary co-pays, ensuring that seniors can access necessary medications even after private insurers opted out of covering costs.
- Uncertain Long-term Viability: Although the program expires in 2027, potentially leaving beneficiaries without access to medications, CMS officials stated they will closely monitor participation and outcomes to inform future policy decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to fall
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1199.430
Low
950.00
Averages
1192
High
1500
Current: 1199.430
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly's Potential in the Growing GLP-1 Market
- Market Growth Outlook: The GLP-1 market is projected to reach $190 billion by 2035, more than doubling its 2025 value, positioning Eli Lilly, as a market leader, to achieve strong returns through ongoing innovation and market share expansion.
- Product Line Diversification: Eli Lilly's drugs like Zepbound and Mounjaro excel in weight loss and diabetes treatment, with Mounjaro emerging as its best-selling product, showcasing the company's robust competitiveness in core therapeutic areas.
- Pipeline Potential: Eli Lilly's investigational drug retatrutide has shown fantastic results in phase 3 trials by mimicking three hormones—GLP-1, GIP, and glucagon—potentially providing new growth momentum and further strengthening its market position.
- Investment Risk Considerations: Despite Eli Lilly's leading position in the GLP-1 market, increasing competition and new drug launches could threaten market share, necessitating investors to carefully assess potential risks to ensure a diversified investment portfolio.
See More
Analysis of the M&A Frenzy in Pharma Industry
- Surge in M&A Activity: In 2026, the pharmaceutical industry has seen 32 deals worth $123 billion, indicating a strong trend towards consolidation, which could mark the most active year since 2019, reflecting urgent market demand for new drug development.
- Patent Cliff Threat: An estimated $300 billion in annual revenue is at risk due to patent expirations in the coming years, with nearly 70 drugs generating over $1 billion each facing patent expiration, compelling pharmaceutical companies to accelerate M&A to find new revenue streams and ensure financial stability.
- Regulatory Environment Shift: Recent significant changes by the FDA regarding approval policies for rare disease treatments allow alternative methods for drug approvals, making clinical-stage drugs more attractive and fueling the M&A frenzy, enhancing market vitality.
- Investor Focus on Individual Companies: While the pharmaceutical industry has underperformed overall, companies like Eli Lilly are demonstrating strong growth potential through aggressive M&A strategies and robust product pipelines, attracting investor interest in their future developments.
See More
Medicare Launches GLP-1 Weight Loss Drug Program for Seniors
- Expanded Drug Coverage: The Centers for Medicare & Medicaid Services announced that starting July 1, millions of seniors will be eligible to receive GLP-1 weight-loss drugs like Wegovy and Zepbound for just $50 per month, significantly enhancing access to weight-loss medications for older Americans.
- Significant Market Impact: The program is expected to add over $1 billion in annual revenue for each of Eli Lilly and Novo Nordisk, further solidifying their dominance in the GLP-1 market, which is projected to generate $150 billion in global sales by 2030.
- Funding Sources: Unlike traditional Medicare, this program is funded by taxpayer dollars and beneficiary co-pays, ensuring that seniors can access necessary medications even after private insurers opted out of covering costs.
- Uncertain Long-term Viability: Although the program expires in 2027, potentially leaving beneficiaries without access to medications, CMS officials stated they will closely monitor participation and outcomes to inform future policy decisions.
See More
Eli Lilly Partners with Innovent Biologics for Verzenio Sales in China
- Sales Transfer: Eli Lilly has transferred the sales rights of Verzenio in mainland China to Innovent Biologics, which will exclusively commercialize the drug, potentially enhancing sales efficiency in the local market.
- Market Performance: In 2022, Verzenio generated approximately 1.5 billion yuan (about $221 million) in sales in China, indicating strong demand and potential in the breast cancer treatment market.
- Increased Competition: With Chinese regulators approving a generic version from Qingfeng Pharmaceutical, although it is not expected to hit the market until Lilly's patent expires in late 2029, this dynamic will intensify market competition and impact Verzenio's market share.
- Strategic Shift: This move allows Lilly to focus on the manufacturing and development of the drug while enhancing its adaptability and competitiveness in the Chinese market through collaboration with a local company.
See More
Wall Street Stocks Rise as AI Investment Momentum Continues
- Market Recovery: Stocks rose on Tuesday as Wall Street looked to cap a strong first half of the year, despite lingering concerns about the Middle East and the sustainability of AI spending, indicating a gradual restoration of investor confidence.
- Stable Oil Prices: Following the U.S. and Iran's agreement, West Texas Intermediate crude held above $70 a barrel, suggesting a reduction in geopolitical risks that could positively impact the global economy.
- Healthcare Stock Rebound: Cardinal Health's stock continued to rally after rebounding from an unjustified sell-off, with CEO Jason Hollar's execution praised, indicating a renewed attractiveness for investments in the healthcare sector.
- Optimistic Outlook for Honeywell Aerospace: Honeywell Aerospace shares rose nearly 2%, with the market undervaluing its independent valuation post-separation, suggesting a potential 35% upside, reflecting growing investor confidence in the aerospace business.
See More
Supreme Court Rulings Have Significant Implications
- Supreme Court Rulings: The Supreme Court ruled that Trump can fire FTC Commissioner Rebecca Slaughter but cannot dismiss Federal Reserve Governor Lisa Cook, indicating a protective stance on independent regulatory bodies that may impact future policy execution and market confidence.
- Market Dynamics: The Dow Jones Industrial Average closed above 52,000 for the first time, bolstered by a nearly 5% rise in Alphabet, although the S&P 500 and Nasdaq Composite are facing downward pressure, reflecting market uncertainty.
- New Medicare Coverage: Starting tomorrow, Medicare will cover obesity drugs for the first time, potentially bringing a large new patient population to Novo Nordisk and Eli Lilly, which could reshape the competitive landscape in obesity treatment.
- Comcast Strategic Shift: Comcast announced plans to spin off NBCUniversal and Sky into a publicly traded company, and while analysts speculate on potential mergers, co-CEO Brian Roberts stated this is not a precursor to M&A, indicating a cautious strategic approach.
See More
Eli Lilly's Potential in the Growing GLP-1 Market
- Market Growth Outlook: The GLP-1 market is projected to reach $190 billion by 2035, more than doubling its 2025 value, positioning Eli Lilly, as a market leader, to achieve strong returns through ongoing innovation and market share expansion.
- Product Line Diversification: Eli Lilly's drugs like Zepbound and Mounjaro excel in weight loss and diabetes treatment, with Mounjaro emerging as its best-selling product, showcasing the company's robust competitiveness in core therapeutic areas.
- Pipeline Potential: Eli Lilly's investigational drug retatrutide has shown fantastic results in phase 3 trials by mimicking three hormones—GLP-1, GIP, and glucagon—potentially providing new growth momentum and further strengthening its market position.
- Investment Risk Considerations: Despite Eli Lilly's leading position in the GLP-1 market, increasing competition and new drug launches could threaten market share, necessitating investors to carefully assess potential risks to ensure a diversified investment portfolio.
See More
Analysis of the M&A Frenzy in Pharma Industry
- Surge in M&A Activity: In 2026, the pharmaceutical industry has seen 32 deals worth $123 billion, indicating a strong trend towards consolidation, which could mark the most active year since 2019, reflecting urgent market demand for new drug development.
- Patent Cliff Threat: An estimated $300 billion in annual revenue is at risk due to patent expirations in the coming years, with nearly 70 drugs generating over $1 billion each facing patent expiration, compelling pharmaceutical companies to accelerate M&A to find new revenue streams and ensure financial stability.
- Regulatory Environment Shift: Recent significant changes by the FDA regarding approval policies for rare disease treatments allow alternative methods for drug approvals, making clinical-stage drugs more attractive and fueling the M&A frenzy, enhancing market vitality.
- Investor Focus on Individual Companies: While the pharmaceutical industry has underperformed overall, companies like Eli Lilly are demonstrating strong growth potential through aggressive M&A strategies and robust product pipelines, attracting investor interest in their future developments.
See More
Medicare Launches GLP-1 Weight Loss Drug Program for Seniors
- Expanded Drug Coverage: The Centers for Medicare & Medicaid Services announced that starting July 1, millions of seniors will be eligible to receive GLP-1 weight-loss drugs like Wegovy and Zepbound for just $50 per month, significantly enhancing access to weight-loss medications for older Americans.
- Significant Market Impact: The program is expected to add over $1 billion in annual revenue for each of Eli Lilly and Novo Nordisk, further solidifying their dominance in the GLP-1 market, which is projected to generate $150 billion in global sales by 2030.
- Funding Sources: Unlike traditional Medicare, this program is funded by taxpayer dollars and beneficiary co-pays, ensuring that seniors can access necessary medications even after private insurers opted out of covering costs.
- Uncertain Long-term Viability: Although the program expires in 2027, potentially leaving beneficiaries without access to medications, CMS officials stated they will closely monitor participation and outcomes to inform future policy decisions.
See More
Eli Lilly Partners with Innovent Biologics for Verzenio Sales in China
- Sales Transfer: Eli Lilly has transferred the sales rights of Verzenio in mainland China to Innovent Biologics, which will exclusively commercialize the drug, potentially enhancing sales efficiency in the local market.
- Market Performance: In 2022, Verzenio generated approximately 1.5 billion yuan (about $221 million) in sales in China, indicating strong demand and potential in the breast cancer treatment market.
- Increased Competition: With Chinese regulators approving a generic version from Qingfeng Pharmaceutical, although it is not expected to hit the market until Lilly's patent expires in late 2029, this dynamic will intensify market competition and impact Verzenio's market share.
- Strategic Shift: This move allows Lilly to focus on the manufacturing and development of the drug while enhancing its adaptability and competitiveness in the Chinese market through collaboration with a local company.
See More
Wall Street Stocks Rise as AI Investment Momentum Continues
- Market Recovery: Stocks rose on Tuesday as Wall Street looked to cap a strong first half of the year, despite lingering concerns about the Middle East and the sustainability of AI spending, indicating a gradual restoration of investor confidence.
- Stable Oil Prices: Following the U.S. and Iran's agreement, West Texas Intermediate crude held above $70 a barrel, suggesting a reduction in geopolitical risks that could positively impact the global economy.
- Healthcare Stock Rebound: Cardinal Health's stock continued to rally after rebounding from an unjustified sell-off, with CEO Jason Hollar's execution praised, indicating a renewed attractiveness for investments in the healthcare sector.
- Optimistic Outlook for Honeywell Aerospace: Honeywell Aerospace shares rose nearly 2%, with the market undervaluing its independent valuation post-separation, suggesting a potential 35% upside, reflecting growing investor confidence in the aerospace business.
See More
Supreme Court Rulings Have Significant Implications
- Supreme Court Rulings: The Supreme Court ruled that Trump can fire FTC Commissioner Rebecca Slaughter but cannot dismiss Federal Reserve Governor Lisa Cook, indicating a protective stance on independent regulatory bodies that may impact future policy execution and market confidence.
- Market Dynamics: The Dow Jones Industrial Average closed above 52,000 for the first time, bolstered by a nearly 5% rise in Alphabet, although the S&P 500 and Nasdaq Composite are facing downward pressure, reflecting market uncertainty.
- New Medicare Coverage: Starting tomorrow, Medicare will cover obesity drugs for the first time, potentially bringing a large new patient population to Novo Nordisk and Eli Lilly, which could reshape the competitive landscape in obesity treatment.
- Comcast Strategic Shift: Comcast announced plans to spin off NBCUniversal and Sky into a publicly traded company, and while analysts speculate on potential mergers, co-CEO Brian Roberts stated this is not a precursor to M&A, indicating a cautious strategic approach.
See More
